Prednisolone or Pentoxifylline for Alcoholic Hepatitis

2015746 citationsJournal Article

Authors

Mark R. Thursz · Royal Liverpool University Hospital

Paul Richardson · Royal Liverpool University Hospital

Michael Allison · Addenbrooke's Hospital

Andrew Austin · Royal Derby Hospital

Megan Bowers · University of Southampton

Christopher P. Day · Newcastle University

Nichola Downs · NIHR Evaluation Trials and Studies Coordinating Centre

Dermot Gleeson

Abstract

Pentoxifylline did not improve survival in patients with alcoholic hepatitis. Prednisolone was associated with a reduction in 28-day mortality that did not reach significance and with no improvement in outcomes at 90 days or 1 year. (Funded by the National Institute for Health Research Health Technology Assessment program; STOPAH EudraCT number, 2009-013897-42 , and Current Controlled Trials number, ISRCTN88782125 ).

Topics & Keywords

Alcohol Consumption and Health Effects Alcoholism and Thiamine Deficiency Liver Disease Diagnosis and Treatment

Publication Details

Published in: New England Journal of Medicine

Volume 372, Issue 17, pp. 1619-1628

DOI: 10.1056/nejmoa1412278

Field-Weighted Citation Impact: 48.08

Command Palette

Prednisolone or Pentoxifylline for Alcoholic Hepatitis

Authors

Abstract

Topics & Keywords

Publication Details